IMPACT OF DARATUMUMAB (DARA) ADMINISTRATION DURING TRANSPLANT- ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) INDUCTION ON STEM CELL (SC) MOBILIZATION COUNT AND POST-TRANSPLANT ENGRAFTMENT EQ Crusoe; A Moura; M Chaves; M Salvino; J Santos; H Santos; A Santos; L Lucas; J Leal; MG Arruda;

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS EQ Crusoe; J Santos; J Leal; H Santos; A Almeida; L Lucas; M Chaves; V Hungria; M Salvino; MG Arruda;

REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EQ Crusoe; GN Ribeiro; FL Moura; AC Neto; M Aranha; RI Bittencourt; EF Ribeiro; JVP Neto; A Maiolino; V Hungria;